Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Flirting with resistance: children's expressions of autonomy during middle childhood.

Kuczynski L, Pitman R, Twigger K.

Int J Qual Stud Health Well-being. 2018;13(sup1):1564519. doi: 10.1080/17482631.2018.1564519.


Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1.

Boelen L, Debebe B, Silveira M, Salam A, Makinde J, Roberts CH, Wang ECY, Frater J, Gilmour J, Twigger K, Ladell K, Miners KL, Jayaraman J, Traherne JA, Price DA, Qi Y, Martin MP, Macallan DC, Thio CL, Astemborski J, Kirk G, Donfield SM, Buchbinder S, Khakoo SI, Goedert JJ, Trowsdale J, Carrington M, Kollnberger S, Asquith B.

Sci Immunol. 2018 Nov 9;3(29). pii: eaao2892. doi: 10.1126/sciimmunol.aao2892.


Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368.


Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2013 May;20(5):521-8. doi: 10.1038/gt.2012.68. Epub 2012 Aug 16.


Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ.

Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7.


A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.

Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, Twigger K, Coffey M, Mettinger K, Gill G, Evans TR, de Bono JS.

Clin Cancer Res. 2011 Feb 1;17(3):581-8. doi: 10.1158/1078-0432.CCR-10-2159. Epub 2010 Nov 24.


REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS.

Clin Cancer Res. 2010 Nov 15;16(22):5564-72. doi: 10.1158/1078-0432.CCR-10-1233. Epub 2010 Oct 6.


Glycoproteomics: a powerful tool for characterizing the diverse glycoforms of bacterial pilins and flagellins.

Hitchen PG, Twigger K, Valiente E, Langdon RH, Wren BW, Dell A.

Biochem Soc Trans. 2010 Oct;38(5):1307-13. doi: 10.1042/BST0381307. Review.


Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA.

Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18.


A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS.

Clin Cancer Res. 2008 Nov 1;14(21):7127-37. doi: 10.1158/1078-0432.CCR-08-0524.


Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA.

Gene Ther. 2008 Sep;15(18):1257-70. doi: 10.1038/gt.2008.58. Epub 2008 Apr 10.


Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ.

Gene Ther. 2008 Jun;15(12):911-20. doi: 10.1038/gt.2008.21. Epub 2008 Mar 6.


Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.

Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ.

Clin Cancer Res. 2008 Feb 1;14(3):912-23. doi: 10.1158/1078-0432.CCR-07-1400.


Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.

Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H, Coffey M, Vile R, Harrington K.

Clin Cancer Res. 2008 Jan 1;14(1):259-69. doi: 10.1158/1078-0432.CCR-07-1510.


Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.

White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG, Melcher AA, Pandha HS, Harrington KJ.

Gene Ther. 2008 Mar;15(6):424-33. Epub 2007 Dec 13.


Supplemental Content

Loading ...
Support Center